AHMEDABAD: Red tapism is pushing India's Rs 1,00,000 crore pharmaceutical industry in peril as most of the pharma companies shifting research and development (R&D) operations and clinical trials to South-East Asian countries of Cambodia, Korea, Philippines, Singapore, Thailand, Vietnam and others, according to a just concluded survey by ASSOCHAM.
"Various South-East Asian countries are wooing India's R&D industry by offering sops and transparent regulations as regulatory bottlenecks and a plethora of committees have slowed permissions/approvals for trials or marketing drugs to more than 12-15 months back home in India while such permissions are given by the USFDA, EU and Singapore within a month's time," according to a survey of Indian Pharma Industry conducted by industry body The Associated Chambers of Commerce and Industry of India (ASSOCHAM).
"Various South-East Asian countries are wooing India's R&D industry by offering sops and transparent regulations as regulatory bottlenecks and a plethora of committees have slowed permissions/approvals for trials or marketing drugs to more than 12-15 months back home in India while such permissions are given by the USFDA, EU and Singapore within a month's time," according to a survey of Indian Pharma Industry conducted by industry body The Associated Chambers of Commerce and Industry of India (ASSOCHAM).
No comments:
Post a Comment